科研之友
微信
新浪微博
Facebook
分享链接
摘要
introduction: the overexpression of human epidermal growth factor receptor (her-2/neu) protein and the amplification of its gene are indicators of more aggressive behavior in breast cancer. the food and drug administration (fda) has approved herceptestˋ with the goal of selecting patients to be elegible for treatment with the humanized murine monoclonal antibody anti-her-2/neu (trastuzumab). aims: the aim of the present study was to compare the results of her-2/neu expression using routine immunohistochemistry method lsabˋ+ (dakocytomation polyclonal antibody a0485) and herceptestˋ. material and methods: 50 cases of breast carcinoma previously evaluated for her-2/neu expression by routine immunohistochemistry using the lsab+ method were included. these cases were also evaluated for her-2/neu expression using herceptestˋ for comparison. results: 34 cases of breast carcinoma were negative for her-2/neu expression by the two methods, with score 0 by herceptestˋ. in 12 and 22 cases, respectively, score 1+ and 0 were observed by the lsabˋ+ method. in eight cases, score 2+ was present by both methods. score 3+ was found in eight cases also by both methods. discussion: the most common method used in routine clinical practice to determine her-2/neu status is immunohistochemistry. variability of her-2/neu results can be caused by a number of variables including time of fixation, methods of epitope retrieval and type of primary antibodies used. conclusion: the conclusion of the present study was that lsabˋ+ and herceptestˋ revealed equivalent results for her-2/neu expression in breast carcinoma.
